Taplitumomab paptox Reference: HY-P99577 Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
Metelimumab Reference: HY-P99305 Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1.
Barecetamab Reference: HY-P99461 Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Batoclimab Reference: HY-P99009 Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies.
Ongericimab Reference: HY-P99773 Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia.
Avizakimab Reference: HY-P99451 Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21.
Anrukinzumab Reference: HY-P99439 Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma.
Amatuximab Reference: HY-P99006 Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium.
Vobarilizumab Reference: HY-P99385 Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
Vulinacimab Reference: HY-P99516 Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells.
Zilovertamab Reference: HY-P99201 Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
Pembrolizumab Reference: HY-P9902 Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.